Smith Group Asset Management’s Kite Pharma, Inc. KITE Stock Holding History

Smith Group Asset Management’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-9,860	Closed	-$1.02M	–	490
2017 Q2	$1.02M	Buy	9,860 +2,920	+42%	+$238K	0.03%	166
2017 Q1	$545K	Sell	6,940 -194	-3%	-$12K	0.02%	181
2016 Q4	$316K	Buy	7,134 +98	+1%	+$4.81K	0.01%	219
2016 Q3	$391K	Buy	7,036 +86	+1%	+$4.79K	0.01%	198
2016 Q2	$348K	Sell	6,950 -100	-1%	-$4.91K	0.01%	208
2016 Q1	$324K	Sell	7,050 -80	-1%	-$3.88K	0.01%	176
2015 Q4	$439K	Buy	+7,130	New	+$502K	0.01%	207

Other funds holding KITE

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCSAM

Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Smith Group Asset Management's KITE Position: Q3 2017 in Review

Smith Group Asset Management sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 9,860 shares — an estimated $1.02M sold.

Smith Group Asset Management first reported a position in KITE in Q4 2015 and held it in 7 quarters. The position peaked at $1.02M in Q2 2017. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

Smith Group Asset Management reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
Smith Group Asset Management sold 9,860 Kite Pharma, Inc. shares in Q3 2017, an estimated $1.02M.
Smith Group Asset Management first reported a position in Kite Pharma, Inc. in Q4 2015 and held it in 7 quarters.
Smith Group Asset Management's Kite Pharma, Inc. position peaked at $1.02M in Q2 2017.
244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Smith Group Asset Management's 13F filing for Q3 2017, filed 2 Nov 2017.